keyword
MENU ▼
Read by QxMD icon Read
search

survival improvement in patients with pancreatic cancer

keyword
https://www.readbyqxmd.com/read/29143898/the-multidisciplinary-approach-to-localized-pancreatic-adenocarcinoma
#1
REVIEW
Hiral D Parekh, Jason Starr, Thomas J George
Pancreatic adenocarcinoma 2030 (PCa) is predicted to be the second leading cause of cancer death in USA by 2030. To date, attempts at early detection have been unsuccessful. Therapies for resectable PCa include surgery followed by adjuvant chemotherapy with or without radiotherapy. Unfortunately, most patients with PCa present with advanced disease and thus only 20% of patients are potentially resectable upon presentation. Improved surgical techniques along with adjuvant combination chemotherapy have improved outcomes for patients with resectable disease...
November 16, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29137355/a-pilot-study-evaluating-concordance-between-blood-based-and-patient-matched-tumor-molecular-testing-within-pancreatic-cancer-patients-participating-in-the-know-your-tumor-kyt-initiative
#2
Michael J Pishvaian, R Joseph Bender, Lynn M Matrisian, Lola Rahib, Andrew Hendifar, William A Hoos, Sam Mikhail, Vincent Chung, Vincent Picozzi, Craig Heartwell, Kimberly Mason, Katelyn Varieur, Metasebia Aberra, Subha Madhavan, Emanuel Petricoin, Jonathan R Brody
Recent improvements in next-generation sequencing (NGS) technology have enabled detection of biomarkers in cell-free DNA in blood and may ultimately replace invasive tissue biopsies. However, a better understanding of the performance of blood-based NGS assays is needed prior to routine clinical use. As part of an IRB-approved molecular profiling registry trial of pancreatic ductal adenocarcinoma (PDA) patients, we facilitated blood-based NGS testing of 34 patients from multiple community-based and high-volume academic oncology practices...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29125367/recent-advances-in-the-management-of-pancreatic-adenocarcinoma
#3
Yusuf Karakas, Sahin Lacin, Suayib Yalcin
Pancreatic cancer (PC) demonstrates very poor prognosis and its incidence continues to increase, despite developments in chemotherapy, radiotherapy, and targeted therapies. Surgical resection is currently the only curative approach for PC. The role of radiotherapy in adjuvant and locally advanced PC continues to be increasingly controversial. This review article aims to explore the current knowledge of pancreatic adenocarcinoma, focusing on diagnosis, treatment strategies, and the best supportive care. Areas covered: The current literature on pancreatic adenocarcinoma treatment modalities has been summarized, with a focus on clinical trials and reviews...
November 13, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29115632/synergistic-effects-of-the-combination-of-5-aza%C3%A2-cdr-and-suberoylanilide-hydroxamic-acid-on-the-anticancer-property-of-pancreatic-cancer
#4
Ting Han, Meng Zhuo, Hai Hu, Feng Jiao, Li-Wei Wang
Despite increasing advances in the diagnosis and treatment for pancreatic cancer, the mortality rate remains high world-wide. There is an urgent need for new therapies to improve survival and quality of life for pancreatic cancer patient. Epigenetic therapeutic agents such as 5-Aza‑CdR and suberoylanilide hydroxamic acid (SAHA) have shown therapeutic effects for human cancers. We evaluated the efficacy of 5-Aza‑CdR or SAHA and their combination as potential therapies for pancreatic cancer in vitro. Treatment with 5-Aza‑CdR or SAHA inhibited pancreatic cancer cell proliferation, migration and induced cell arrest...
October 31, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29113401/optimal-adjuvant-chemotherapy-for-resected-pancreatic-adenocarcinoma-a-systematic-review-and-network-meta-analysis
#5
Jian-Bo Xu, Bin Jiang, Ya Chen, Fu-Zhen Qi, Jian-Huai Zhang, Hang Yuan
Adjuvant chemotherapy improves survival in patients with resected pancreatic cancer but the optimal regimen remains unclear. We aim to compare all possible adjuvant chemotherapy in terms of overall survival and toxic effects. Pubmed, Trial registries and Cochrane library databases for randomized controlled trials were searched until November 2016. Thirteen trials were included for network analysis and the hazard ratios (HRs) for survival and odds ratios for toxic effects were assessed via Aggregate Data Drug Information System software...
October 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/29108359/surgical-resection-of-primary-tumor-improves-survival-of-pancreatic-neuroendocrine-tumor-with-liver-metastases
#6
Lianyuan Tao, Dianrong Xiu, Abuduhaibaier Sadula, Chen Ye, Qing Chen, Hanyan Wang, Zhipeng Zhang, Lingfu Zhang, Ming Tao, Chunhui Yuan
This study investigates survival of patients diagnosed with pancreatic neuroendocrine tumor with liver metastases based on local treatment on the primary tumor. Patients diagnosed with stage IV PNET between 2010 and 2014 were identified from the Surveillance Epidemiology and End Results database. Cancer-Specific Survival and Overall Survival were examined. A total of 191 patients with pancreatic neuroendocrine tumor with liver metastases were included in this analysis. There were 47 patients (24.6%) who received surgical resection and 144 (75...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29101736/clinical-implications-of-nras-overexpression-in-resectable-pancreatic-adenocarcinoma-patients
#7
Javier Martinez-Useros, Weiyao Li, Tihomir Georgiev-Hristov, Maria J Fernandez-Aceñero, Aurea Borrero-Palacios, Nuria Perez, Angel Celdran, Jesus Garcia-Foncillas
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer, and its incidence is rising worldwide. Although survival can be improved by surgical resection, when detected at an early stage, this type of cancer is usually asymptomatic, and disease becomes only apparent after metastasis. Adjuvant treatment does not improve survival, thus after surgery there is a lack of predictive and prognosis biomarkers to predict treatment response and survival. The mitogen-activated protein-kinase and phosphoinositide 3-kinase signalling pathways play a crucial role in cancer development and progression...
November 3, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/29101568/minimally-invasive-surgical-approaches-offer-earlier-time-to-adjuvant-chemotherapy-but-not-improved-survival-in-resected-pancreatic-cancer
#8
Katelin A Mirkin, Erin K Greenleaf, Christopher S Hollenbeak, Joyce Wong
BACKGROUND: Pancreatic surgery encompasses complex operations with significant potential morbidity. Greater experience in minimally invasive surgery (MIS) has allowed resections to be performed laparoscopically and robotically. This study evaluates the impact of surgical approach in resected pancreatic cancer. METHODS: The National Cancer Data Base (2010-2012) was reviewed for patients with stages 1-3 resected pancreatic carcinoma. Open approaches were compared to MIS...
November 3, 2017: Surgical Endoscopy
https://www.readbyqxmd.com/read/29099030/repurposing-established-compounds-to-target-pancreatic-cancer-stem-cells-cscs
#9
REVIEW
Bernhard W Renz, Jan G D'Haese, Jens Werner, C Benedikt Westphalen, Matthias Ilmer
The diagnosis of pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis, in particular, when patients present with unresectable disease. While significant progress has been made in understanding the biology of PDAC, this knowledge has not translated into a clear clinical benefit and current chemotherapeutic strategies only offer a modest improvement in overall survival. Accordingly, novel approaches are desperately needed. One hypothesis that could-at least in part-explain the desolate response of PDAC to chemotherapy is the so-called cancer stem cell (CSC) concept, which attributes specific traits, such as chemoresistance, metastatic potential and a distinct metabolism to a small cellular subpopulation of the whole tumor...
June 19, 2017: Medical Sciences: Open Access Journal
https://www.readbyqxmd.com/read/29094028/survival-outcome-and-prognostic-factors-of-neoadjuvant-treatment-followed-by-resection-for-borderline-resectable-pancreatic-cancer
#10
Hyeong Seok Kim, Jin-Young Jang, Youngmin Han, Kyoung Bun Lee, Ijin Joo, Doo-Ho Lee, Jae Ri Kim, Hongbeom Kim, Wooil Kwon, Sun-Whe Kim
Purpose: Neoadjuvant treatment may provide improved survival outcomes for patients with borderline resectable pancreatic cancer (BRPC). The purpose of this study is to evaluate the clinical outcomes of neoadjuvant treatment and to identify prognostic factors. Methods: Forty patients who met the National Comprehensive Cancer Network definition of BRPC and received neoadjuvant treatment followed by surgery between 2007 and 2015 were evaluated. Prospectively collected clinicopathological outcomes were analyzed retrospectively...
October 2017: Annals of Surgical Treatment and Research
https://www.readbyqxmd.com/read/29081375/dose-surgical-resection-of-hepatic-metastases-bring-benefits-to-pancreatic-ductal-adenocarcinoma-a-systematic-review-and-meta-analysis
#11
REVIEW
Xinzhe Yu, Jichun Gu, Deliang Fu, Chen Jin
OBJECTIVE: The objectives of this systematic review and meta-analysis were to examine morbidity, mortality, and long-term survival after surgical resection of hepatic metastases from pancreatic ductal adenocarcinoma (PDAC) patients. BACKGROUND: Patients with hepatic metastases from pancreatic ductal adenocarcinoma are facing a dilemma of whether to make hepatic resection. METHODS: A systematic literature research was undertaken through computerized databases as well as manually research from unpublished data...
November 2, 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/29068800/the-impact-of-positive-resection-margins-on-survival-and-recurrence-following-resection-and-adjuvant-chemotherapy-for-pancreatic-ductal-adenocarcinoma
#12
Paula Ghaneh, Jorg Kleeff, Christopher M Halloran, Michael Raraty, Richard Jackson, James Melling, Owain Jones, Daniel H Palmer, Trevor F Cox, Chloe J Smith, Derek A O'Reilly, Jakob R Izbicki, Andrew G Scarfe, Juan W Valle, Alexander C McDonald, Ross Carter, Niall C Tebbutt, David Goldstein, Robert Padbury, Jennifer Shannon, Christos Dervenis, Bengt Glimelius, Mark Deakin, Alan Anthoney, Markus M Lerch, Julia Mayerle, Attila Oláh, Charlotte L Rawcliffe, Fiona Campbell, Oliver Strobel, Markus W Büchler, John P Neoptolemos
OBJECTIVE AND BACKGROUND: Local and distant disease recurrence are frequently observed following pancreatic cancer resection, but an improved understanding of resection margin assessment is required to aid tailored therapies. METHODS: Analyses were carried out to assess the association between clinical characteristics and margin involvement as well as the effects of individual margin involvement on site of recurrence and overall and recurrence-free survival using individual patient data from the European Study Group for Pancreatic Cancer (ESPAC)-3 randomized controlled trial...
October 24, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/29058490/incidence-diagnostic-treatment-and-outcome-of-patients-diagnosed-with-cancer-of-the-pancreas-during-1986-2009-a-population-based-study
#13
Sara B Jonsdottir, Gunnar Juliusson, Jon Ö Kristinsson, Johann P Hreinsson, Jon G Jonasson, Einar S Björnsson
OBJECTIVE: Limited data exist on the changes in the epidemiology of pancreatic cancer and outcomes over the last decades in population-based cohorts. We aimed to compare the incidence of pancreatic cancer, diagnostic, treatment and survival among patients diagnosed over the period 1986-2009. MATERIALS AND METHODS: A retrospective, nationwide, population-based study. All patients diagnosed with pancreatic cancer in Iceland in two periods, 1986-1997 (P1) and 1998-2009 (P2) were identified through the Icelandic Cancer Registry and relevant clinical information obtained from medical records...
October 23, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/29056856/surgical-resection-of-a-primary-tumor-improves-survival-of-metastatic-pancreatic-cancer-a-population-based-study
#14
Lianyuan Tao, Chunhui Yuan, Zhaolai Ma, Bin Jiang, Dianrong Xiu
INTRODUCTION: Pancreatic cancer is a lethal disease with a very poor prognosis. This study investigates survival of patients diagnosed with metastatic pancreatic cancer (mPC) based on local treatment of the primary tumor. METHODS: Patients diagnosed with stage IV mPC between 2004 and 2013 were identified from the Surveillance, Epidemiology and End Results (SEER) database. Cancer-specific survival (CSS) and overall survival (OS) were examined. CSS and OS were examined by using the Kaplan-Meier method with the log-rank test...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/29055078/neoadjuvant-chemoradiation-for-non-metastatic-pancreatic-cancer-increases-margin-negative-and-node-negative-rates-at-resection
#15
Camille A Berriochoa, May Abdel-Wahab, Charles Marc Leyrer, Alok Khorana, R Matthew Walsh, Aryavarta M S Kumar
AIM: Preoperative chemoradiation for non-metastatic pancreatic cancer patients has been associated with improved outcomes; however, direct comparisons to adjuvant therapy are limited. METHODS: Single institution data were obtained for non-metastatic pancreatic cancer patients treated with concurrent chemoradiation +/- resection from 2011-2014. Univariate analyses were performed to evaluate clinical and pathologic outcomes. RESULTS: Fifty-two well matched patients met inclusion criteria (neoadjuvant chemoradiation = 21, adjuvant chemoradiation = 11, definitive = 20)...
October 20, 2017: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/29040974/an-intergroup-randomized-phase-ii-study-of-bevacizumab-or-cetuximab-in-combination-with-gemcitabine-and-in-combination-with-chemoradiation-in-patients-with-resected-pancreatic-carcinoma-a-trial-of-the-ecog-acrin-cancer-research-group-e2204
#16
Jordan D Berlin, Yang Feng, Paul Catalano, James L Abbruzzese, Philip A Philip, Robert R McWilliams, Andrew M Lowy, Al B Benson Iii, A William Blackstock
OBJECTIVES: Evaluate toxicity of two treatment arms, A (cetuximab) and B (bevacizumab), when combined with gemcitabine, and chemoradiation in patients with completely resected pancreatic carcinoma. Secondary objectives included overall survival (OS) and disease-free survival (DFS). METHODS: Patients with R0/R1 resection were randomized 1:1 to cetuximab or bevacizumab administered in combination with gemcitabine for two treatment cycles. Next three cycles included concurrent cetuximab/bevacizumab plus chemoradiation, followed by one cycle of cetuximab/bevacizumab...
October 18, 2017: Oncology
https://www.readbyqxmd.com/read/29032923/is-it-necessary-to-dissect-the-posterior-lymph-nodes-along-the-splenic-vessels-during-total-gastrectomy-with-d2-lymphadenectomy-for-advanced-gastric-cancer
#17
Jian-Xian Lin, Chang-Ming Huang, Chao-Hui Zheng, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Qi-Yue Chen, Long-Long Cao, Mi Lin
BACKGROUND: D2 lymphadenectomy including No.10 lymph nodes (LNs) is the standard procedure for treating advanced gastric cancer (AGC) via total gastrectomy. However, there was no research focusing on the posterior LN dissection along the splenic vessels (No.10p LNs). This study is performed to assess the effect of dissecting No.10p LNs. METHODS: We analyzed 404 consecutive gastric cancer patients who underwent laparoscopic total gastrectomy (LTG) with D2 lymphadenectomy...
September 19, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29027279/long-non-coding-rna-pvt1-emerging-biomarker-in-digestive-system-cancer
#18
REVIEW
Dan-Dan Zhou, Xiu-Fen Liu, Cheng-Wei Lu, Om Prakash Pant, Xiao-Dong Liu
The digestive system cancers are leading cause of cancer-related death worldwide, and have high risks of morbidity and mortality. More and more long non-coding RNAs (lncRNAs) have been studied to be abnormally expressed in cancers and play a key role in the process of digestive system tumour progression. Plasmacytoma variant translocation 1 (PVT1) seems fairly novel. Since 1984, PVT1 was identified to be an activator of MYC in mice. Its role in human tumour initiation and progression has long been a subject of interest...
October 12, 2017: Cell Proliferation
https://www.readbyqxmd.com/read/29025990/-177-lu-3bp-227-for-neurotensin-receptor-1-targeted-therapy-of-metastatic-pancreatic-adenocarcinoma-first-clinical-results
#19
Richard P Baum, Aviral Singh, Christiane Schuchardt, Harshad Rajaram Kulkarni, Ingo Klette, Stefan Wiessalla, Frank Osterkamp, Ulrich Reineke, Christiane Smerling
Neurotensin receptor 1 (NTR1) is overexpressed in ductal pancreatic adenocarcinoma, which is still one of the deadliest cancers with a very poor prognosis. Eligible patients were offered radiopharmaceutical treatment with the novel NTR1 antagonist (177)Lu-3BP-227 as salvage therapy. Methods: Six patients with confirmed ductal pancreatic adenocarcinoma who had exhausted all other treatment options received (177)Lu-3BP-227 for evaluation of NTR1 expression in vivo. Three patients received treatment activities between 5...
October 12, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29018912/a-nationwide-population-based-study-on-the-survival-of-patients-with-pancreatic-neuroendocrine-tumors-in-the-netherlands
#20
C G Genc, H J Klümpen, M G H van Oijen, C H J van Eijck, E J M Nieveen van Dijkum
BACKGROUND: Large population-based studies give insight into the prognosis and treatment outcomes of patients with pancreatic neuroendocrine tumors (pNETs). Therefore, we provide an overview of the treatment and related survival of pNET in the Netherlands. METHODS: Patients diagnosed with pNET between 2008 and 2013 from the Netherlands Cancer Registry were included. Patient, tumors and treatment characteristics were reported. Survival analyses with log-rank testing were performed to compare survival...
October 10, 2017: World Journal of Surgery
keyword
keyword
66462
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"